Boruzu
Boruzu ingredients
| Active ingredient | Strength |
|---|---|
| Bortezomib | 3.5 mg/1.4mL |
What Boruzu is used for
The FDA lists the approved uses on the official label (below). In the EU, bortezomib is approved as Velcade for:
Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation. Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation. Velcade in combination with rituximab, cyclophosphamide, doxorubicin …
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Boruzu
- Generic name
- Bortezomib
- Made by
- Amneal Pharmaceuticals LLC
- Forms
- Injection
- Given
- Intravenous, Subcutaneous
- Drug class
- Proteasome Inhibitor
- FDA approval
- New drug application (NDA) NDA212782
- On the US market since
- 2024
Official information
- Boruzu prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Bortezomib)
In India
- Bortezomib: 47 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Boruzu?
Boruzu (Bortezomib) is a cancer medicine made by Amneal Pharmaceuticals LLC, approved by the US FDA.
What are the ingredients of Boruzu?
Boruzu contains Bortezomib (3.5 mg/1.4mL).
Is Boruzu approved in Europe?
The same active substance is approved in the EU as Velcade.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA